trending Market Intelligence /marketintelligence/en/news-insights/trending/GqHXvLoj-wb3dE7aIpmMIA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Lannett receives FDA's supplemental approval for morphine solution

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Lannett receives FDA's supplemental approval for morphine solution

Lannett Co. Inc. received approval from the U.S. FDA for the supplemental new drug application of its morphine sulfate oral solution CII.

The solution is an opioid agonist indicated for the management of acute and chronic pain in opioid-tolerant patients severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Lannett CEO Arthur Bedrosian stated that the company expects to launch the solution soon.

Total U.S. sales for the 12 months ended October for morphine sulfate oral solution, at average wholesale price, were about $22 million, according to IMS Health data.